Back10x Genomics Overview
10x Genomics Inc - Ordinary Shares - Class A

10x Genomics Target Price

See 10x Genomics's analyst price targets ($39) vs the current share price.

Get informed when a big investor buys or sells

+ Follow

Share Price

$57.75

Average Target Price

$38.6333.1% downside

8 analysts in the last 4 months

High: $50 | Low: $22

Analyst Recommendations

No recommendations in the last 4 months.

Revenue & Income Forecast

Analysts' Target Prices

DateAnalystPrice TargetCurrent Upside/Downside
2026-08-07Morgan Stanley$4030.7% downsideOpen
2026-08-07Stifel Nicolaus$5013.4% downsideOpen
2026-07-17Leerink Partners$4030.7% downsideOpen
2026-07-14Canaccord GenuityKyle Mikson$5013.4% downsideOpen
2026-07-09Morgan StanleyKallum Titchmarsh$3735.9% downsideOpen
2026-06-24BarclaysLuke Sergott$4030.7% downsideOpen
2026-05-12Morgan Stanley$2261.9% downsideOpen
2026-04-14Barclays$3048.1% downsideOpen
2026-03-02Stifel NicolausDaniel Arias$2556.7% downsideOpen
2026-02-20UBS$2065.4% downsideOpen
2026-02-13Deutsche Bank$1770.6% downsideOpen
2026-02-13Stifel Nicolaus$2065.4% downsideOpen
2026-02-13Canaccord GenuityKyle Mikson$2261.9% downsideOpen
2026-01-12Needham$2163.6% downsideOpen
2025-12-22Canaccord Genuity$2065.4% downsideOpen
2025-12-15Barclays$2261.9% downsideOpen
2025-12-01Morgan StanleyKallum Titchmarsh$2065.4% downsideOpen
2025-08-11Canaccord GenuityKyle Mikson$1672.3% downsideOpen
2025-08-08UBSDan Leonard$1377.5% downsideOpen
2025-08-08Deutsche BankJustin Bowers$1475.8% downsideOpen
2024-08-13Morgan StanleyTejas Savant$4620.3% downsideOpen
2024-07-23Canaccord GenuityKyle Mikson$3244.6% downsideOpen
2024-07-10Deutsche BankJustin Bowers$2556.7% downsideOpen
2024-06-28BarclaysLuke Sergott$2458.4% downsideOpen
2024-06-03JefferiesTycho Peterson$2458.4% downsideOpen
2024-05-01BarclaysLuke Sergott$3637.7% downsideOpen
2024-04-10BarclaysLuke Sergott$4522.1% downsideOpen
2022-12-14Deutsche Bank$5013.4% downsideOpen

10x Genomics (TXG) FAQ

10x Genomics posts a target price of $39. Comparing that reading with peers and prior periods is usually more useful than looking at the number in isolation.

A target price of $39 for TXG means covering analysts, on average, see the stock 33.1% downside of $57.75 over about 12 months. Dig into who set the high and low targets and how recently they updated — freshness matters as much as the average itself.

Context for TXG's target price usually means three checks: (1) trend versus prior periods, (2) level versus peers, and (3) consistency with growth and profitability. This page covers the first two; 10x Genomics's other metric pages and overview cover the third.

Judging 10x Genomics against Healthcare peers is usually better than using a market-wide rule of thumb. Business models inside Healthcare are more comparable, which makes gaps in target price easier to interpret. Start with $39 here, then scan peer and history charts to see if the gap is persistent.